AGIOS PHARMACEUTICALS INC will stop developing tebapivat for blood cancer after a mid-stage trial failed to meet efficacy goals. Shares fell 1.7% in the United States during morning trading following the announcement. The failure narrows the pipeline for the rare-disease specialist as it pivots toward sickle cell treatments.

Why Tebapivat Failed the Efficacy Test